CTIC Stock Performance, Insider Transaction and News

CTIC - CTI BioPharma Corp.

Market Cap	1.20B	P/E	-	EPS this Y	61.70%	Ern Qtrly Grth	-
Income	-69.24M	Forward P/E	101.00	EPS next Y	129.00%	50D Avg Chg	19.00%
Sales	75.77M	PEG	-	EPS past 5Y	-	200D Avg Chg	55.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	-	52W High Chg	-
Recommedations	2.20	Quick Ratio	1.20	Shares Outstanding	131.88M	52W Low Chg	127.00%
Insider Own	5.50%	ROA	-28.58%	Shares Float	99.89M	Beta	0.83
Inst Own	83.29%	ROE	-	Shares Shorted/Prior	11.27M/12.17M	Price	9.09
Gross Margin	94.11%	Profit Margin	-91.38%	Avg. Volume	6,224,763	Target Price	10.37
Oper. Margin	-73.54%	Earnings Date	Aug 7	Volume	11,420,980	Change	0.00%

Healthcare | Biotechnology | United States

About CTI BioPharma Corp.

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

CTIC Chatroom

frbdcsbjax Posted - 03/29/24

$CTIC anyone here?

CruBones Posted - 1 month ago

@cheetohottaki look at how $ctic behaved before buy out

pharmde Posted - 1 month ago

@spartaksus interesting to see $CTIC had 2 bidders. It was unfortunate that they only got bought after FDA approval and after a few months of sales only for a 2x gain. Maybe Mirati, but we are definitely not a Seagen

Micky11 Posted - 1 month ago

@bankrupt_bob @Gaucho12 should be no problem big short have seen it before with $CTIC bought out with 28M short last year. That's a good middlefinger to the shorts Ardelyx will be bought out one day .The news will happen suddenly if not now maybe next year.

AlexPEC Posted - 3 months ago

$LIFE The 900,000 $1.5 Employee Stock Option (right to buy) incentive acquired by CEO/CFO/GC is crazy, so affirmative to buyout or growth. Just like $CTIC buyout three months ago. But I rather love to grow with company gradually.

SoldTooSoon Posted - 4 months ago

@cobragene I messed up with $ctic had xx,xxx shares under $2, sold it around 4 should have held it for a year and would have been $8.... Lesson learned..

MRKR2025 Posted - 4 months ago

$IMGN $CTIC $MRTX $IOVA Never owned CTIC, owned MRTX way back when they were Canadian MethylGene, held and did well, owned IMGN and sold it at a loss and never bought back in so missed it all, waiting for IOVA to pay off Big Time.

Night_Owl_Biotech Posted - 4 months ago

The attachment documents the enterprise value & 10-year revenue estimates of $IOVA compared to the 3 oncology focused bios acquired in 2023 including $CTIC, $MRTX & $IMGN. It is interesting to note IOVA is expected to generate roughly the same revenue profile the first 5 years as IMGN that was just acquired for an enterprise value of $9.6Billion (of course IOVA may produce lower gross margins). In July 2023 institutional investors purchased ~$160MM worth of IOVA at $7.50/share. IOVA has a 2/24/24 PDUFA date for Lifileucel. If the FDA issues a CRL then IOVA could be worthless. We have no idea what will happen to IOVA's share price. Otherwise, as always do your own due diligence. We are simply sharing our observations & analysis.

Night_Owl_Biotech Posted - 11/30/23

@audi999999 @therealcaptainamerica Attached is a simple comparison of the $IOVA peer valuation related data points from the 3 most recent oncology focused M&A transactions. FY2027 & FY2028 consensus revenue estimates are per Seeking Alpha. If the data points are accurate, especially the patent related dates, then it suggests IOVA's Lifileucel is worth north of 3.6X FY2028 consensus revenue estimates (assuming patented through 2038) if approved & if revenue estimates are credible. $MRTX & $CTIC were acquired at 0.26X Year 5 consensus revenue estimates for each year of patent life remaining. It appears $IMGN is being acquired at 0.38X Year 5 assuming Elahere revenues if patented through 2043 as noted in their last 10K. Put simplest, simple analytics suggests the $IMGN acquisition is a very important valuation inflection point for IOVA should Lifileucel be approved. As always, we could be very wrong.

Night_Owl_Biotech Posted - 5 months ago

Our hypothetical/theoretical $IOVA valuation 2 years from now if; 1. Lifileucel is approved and if; 2. LN-145 continues to look like it will be approved and if; 3. IOVA FY2030 consensus revenue estimates are more or less unchanged and if; 4. Our patent date assumptions are accurate and if; 5. IOVA is acquired at $MRTX & $CTIC 5-year multiples per year to LOE. 6. 3 other things happen as noted in the video We're not suggesting investing in IOVA. This is not investment advice. It is as likely IOVA will fail. We've been very wrong before. IOVA could go bankrupt. We're only sharing a hypothetical w Good luck. https://www.youtube.com/watch?v=o5WPL2vlvSs

Night_Owl_Biotech Posted - 5 months ago

Our new YouTube video (link below) calculates the theoretical market cap of $BCRX if it were to be acquired today at revenue multiples consistent with the $MRTX & $CTIC acquisitions. BCRX has gross margins @ 99% (on par with MRTX/CTIC). The video is for entertainment purposes only. We do not recommend you buy or sell any particular stock as we have no idea how a particular company nor the markets as a whole will trade in the future. Also, the video is dated 11/6/23 & the data presented is unaudited. Do not rely on our analysis. https://www.youtube.com/watch?v=Dv20cxqhcdc&feature=youtu.be

TrendyChart Posted - 10/26/23

Upcoming Earnings Report: $CTIC CTI BioPharma will be reporting on 11/06/2023 at 4:00PM | Do you have a rosy or gloomy earnings perspective for this stock?